164 related articles for article (PubMed ID: 24871550)
1. The effect of polysorbate 20 on solubility and stability of candesartan cilexetil in dissolution media.
Hoppe K; Sznitowska M
AAPS PharmSciTech; 2014 Oct; 15(5):1116-25. PubMed ID: 24871550
[TBL] [Abstract][Full Text] [Related]
2. DEVELOPMENT AND VALIDATION OF HPLC ANALYTICAL METHODS USED-FOR DETERMINATION OF ASSAY, CONTENT UNIFORMITY AND DISSOLUTION OF IMMEDIATE RELEASE CANDESARTAN CILEXETIL 32 MG TABLETS.
Yuce M; Capan Y
Acta Pol Pharm; 2017 Mar; 74(2):357-367. PubMed ID: 29624240
[TBL] [Abstract][Full Text] [Related]
3. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.
Jain S; Reddy VA; Arora S; Patel K
Drug Deliv Transl Res; 2016 Oct; 6(5):498-510. PubMed ID: 27129488
[TBL] [Abstract][Full Text] [Related]
4. Development and in vitro/in vivo performance of self-nanoemulsifying drug delivery systems loaded with candesartan cilexetil.
AboulFotouh K; Allam AA; El-Badry M; El-Sayed AM
Eur J Pharm Sci; 2017 Nov; 109():503-513. PubMed ID: 28889028
[TBL] [Abstract][Full Text] [Related]
5. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
Dudhipala N; Veerabrahma K
Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
[TBL] [Abstract][Full Text] [Related]
6. Candesartan cilexetil microemulsions for transdermal delivery: formulation, in-vitro skin permeation and stability assessment.
Malakar J; Basu A; Nayak AK
Curr Drug Deliv; 2014; 11(3):313-21. PubMed ID: 24893994
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of solubility and permeability of Candesartan cilexetil by using different pharmaceutical interventions.
Shaikh SM; Avachat AM
Curr Drug Deliv; 2011 Jul; 8(4):346-53. PubMed ID: 21453263
[TBL] [Abstract][Full Text] [Related]
8. Solid self-microemulsifying formulation for candesartan cilexetil.
Nekkanti V; Karatgi P; Prabhu R; Pillai R
AAPS PharmSciTech; 2010 Mar; 11(1):9-17. PubMed ID: 20013081
[TBL] [Abstract][Full Text] [Related]
9. Development and characterization of solid oral dosage form incorporating candesartan nanoparticles.
Nekkanti V; Pillai R; Venkateshwarlu V; Harisudhan T
Pharm Dev Technol; 2009; 14(3):290-8. PubMed ID: 19235553
[TBL] [Abstract][Full Text] [Related]
10. Novel tablet formulation of amorphous candesartan cilexetil solid dispersions involving P-gp inhibition for optimal drug delivery: in vitro and in vivo evaluation.
Surampalli G; Nanjwade BK; Patil PA; Chilla R
Drug Deliv; 2016 Sep; 23(7):2124-2138. PubMed ID: 25080228
[TBL] [Abstract][Full Text] [Related]
11. Solid dispersion systems for enhanced dissolution of poorly water-soluble candesartan cilexetil: In vitro evaluation and simulated pharmacokinetics studies.
Ali ISM; Sajad UA; Abdul Rasool BK
PLoS One; 2024; 19(6):e0303900. PubMed ID: 38843120
[TBL] [Abstract][Full Text] [Related]
12. Comparative Pharmaceutical Evaluation of Candesartan and Candesartan Cilexetil: Physicochemical Properties, In Vitro Dissolution and Ex Vivo In Vivo Studies.
Amer AM; Allam AN; Abdallah OY
AAPS PharmSciTech; 2018 Feb; 19(2):661-667. PubMed ID: 28948575
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of mixed niosomes for oral delivery using candesartan cilexetil as a model poorly water-soluble drug.
Sezgin-Bayindir Z; Antep MN; Yuksel N
AAPS PharmSciTech; 2015 Feb; 16(1):108-17. PubMed ID: 25204859
[TBL] [Abstract][Full Text] [Related]
14. The effect of PAMAM dendrimer concentration, generation size and surface functional group on the aqueous solubility of candesartan cilexetil.
Ertürk AS; Gürbüz MU; Tülü M
Pharm Dev Technol; 2017 Feb; 22(1):111-121. PubMed ID: 27484586
[TBL] [Abstract][Full Text] [Related]
15. pH-responsive polymeric micelles of poly(ethylene glycol)-b-poly(alkyl(meth)acrylate-co-methacrylic acid): influence of the copolymer composition on self-assembling properties and release of candesartan cilexetil.
Satturwar P; Eddine MN; Ravenelle F; Leroux JC
Eur J Pharm Biopharm; 2007 Mar; 65(3):379-87. PubMed ID: 17123802
[TBL] [Abstract][Full Text] [Related]
16. Design and optimization of candesartan loaded self-nanoemulsifying drug delivery system for improving its dissolution rate and pharmacodynamic potential.
Verma R; Kaushik D
Drug Deliv; 2020 Dec; 27(1):756-771. PubMed ID: 32397771
[TBL] [Abstract][Full Text] [Related]
17. DEVELOPMENT OF SOLID LIPID NANOCARRIERS FOR ORAL DELIVERY OF CANDESERTAN CILEXETIL.
Ugurlu T; Nalbantoglu A; Sengel-Turk CT
Acta Pol Pharm; 2016 Nov; 73(6):1631-1638. PubMed ID: 29634119
[TBL] [Abstract][Full Text] [Related]
18. Development of self-microemulsifying bilayer tablets for pH-independent fast release of candesartan cilexetil.
Sohn Y; Lee SY; Lee GH; Na YJ; Kim SY; Seong I; Lee BJ; Kuh HJ; Lee J
Pharmazie; 2012 Nov; 67(11):917-24. PubMed ID: 23210241
[TBL] [Abstract][Full Text] [Related]
19. Effect of surfactants and hydrophilic polymers on the stability of an antihypertensive drug candesartan cilexetil: Evaluation by HPLC.
Krishna MV; Sowhardhra M; Kumar MS; Madhavi G; Jadhav T; Thakkar D
Ann Pharm Fr; 2018 Jan; 76(1):32-43. PubMed ID: 29174608
[TBL] [Abstract][Full Text] [Related]
20. Use of compounded dispersing media for extemporaneous pediatric syrups with candesartan cilexetil and valsartan.
Musko M; Sznitowska M
Acta Pharm; 2014 Dec; 64(4):463-74. PubMed ID: 25531786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
